GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00107206 | Cervix | CC | positive regulation of cell development | 64/2311 | 298/18723 | 5.69e-06 | 1.41e-04 | 64 |
GO:00073695 | Cervix | CC | gastrulation | 42/2311 | 185/18723 | 5.83e-05 | 8.46e-04 | 42 |
GO:00605375 | Cervix | CC | muscle tissue development | 76/2311 | 403/18723 | 9.76e-05 | 1.27e-03 | 76 |
GO:00147064 | Cervix | CC | striated muscle tissue development | 72/2311 | 384/18723 | 1.76e-04 | 2.07e-03 | 72 |
GO:00459955 | Cervix | CC | regulation of embryonic development | 19/2311 | 64/18723 | 1.78e-04 | 2.09e-03 | 19 |
GO:0033002 | Cervix | CC | muscle cell proliferation | 49/2311 | 248/18723 | 5.43e-04 | 5.24e-03 | 49 |
GO:00519603 | Cervix | CC | regulation of nervous system development | 77/2311 | 443/18723 | 1.13e-03 | 9.30e-03 | 77 |
GO:00507676 | Cervix | CC | regulation of neurogenesis | 65/2311 | 364/18723 | 1.33e-03 | 1.05e-02 | 65 |
GO:00507694 | Cervix | CC | positive regulation of neurogenesis | 43/2311 | 225/18723 | 2.25e-03 | 1.61e-02 | 43 |
GO:0014855 | Cervix | CC | striated muscle cell proliferation | 18/2311 | 76/18723 | 4.45e-03 | 2.71e-02 | 18 |
GO:00519622 | Cervix | CC | positive regulation of nervous system development | 48/2311 | 272/18723 | 6.60e-03 | 3.65e-02 | 48 |
GO:00605376 | Endometrium | AEH | muscle tissue development | 83/2100 | 403/18723 | 2.57e-08 | 1.50e-06 | 83 |
GO:00147065 | Endometrium | AEH | striated muscle tissue development | 75/2100 | 384/18723 | 1.06e-06 | 3.62e-05 | 75 |
GO:00330022 | Endometrium | AEH | muscle cell proliferation | 51/2100 | 248/18723 | 1.26e-05 | 2.77e-04 | 51 |
GO:00107207 | Endometrium | AEH | positive regulation of cell development | 57/2100 | 298/18723 | 3.72e-05 | 6.49e-04 | 57 |
GO:00459956 | Endometrium | AEH | regulation of embryonic development | 18/2100 | 64/18723 | 1.65e-04 | 2.15e-03 | 18 |
GO:0048738 | Endometrium | AEH | cardiac muscle tissue development | 43/2100 | 236/18723 | 9.06e-04 | 8.30e-03 | 43 |
GO:0035265 | Endometrium | AEH | organ growth | 33/2100 | 178/18723 | 2.53e-03 | 1.87e-02 | 33 |
GO:00507677 | Endometrium | AEH | regulation of neurogenesis | 56/2100 | 364/18723 | 8.87e-03 | 4.82e-02 | 56 |
GO:006053713 | Endometrium | EEC | muscle tissue development | 82/2168 | 403/18723 | 2.14e-07 | 9.38e-06 | 82 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TENM4 | SNV | Missense_Mutation | | c.385G>A | p.Val129Met | p.V129M | Q6N022 | protein_coding | tolerated_low_confidence(0.8) | benign(0.018) | TCGA-BD-A3EP-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TENM4 | SNV | Missense_Mutation | novel | c.7700G>A | p.Gly2567Asp | p.G2567D | Q6N022 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CC-A9FW-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
TENM4 | SNV | Missense_Mutation | novel | c.8242N>A | p.Tyr2748Asn | p.Y2748N | Q6N022 | protein_coding | deleterious(0.01) | possibly_damaging(0.726) | TCGA-DD-AACZ-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
TENM4 | SNV | Missense_Mutation | | c.5489N>A | p.Arg1830Gln | p.R1830Q | Q6N022 | protein_coding | deleterious(0.01) | probably_damaging(0.978) | TCGA-DD-AACZ-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
TENM4 | SNV | Missense_Mutation | novel | c.745N>C | p.Thr249Pro | p.T249P | Q6N022 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-DD-AADO-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TENM4 | SNV | Missense_Mutation | novel | c.4099N>G | p.Thr1367Ala | p.T1367A | Q6N022 | protein_coding | deleterious(0) | probably_damaging(0.97) | TCGA-ED-A8O5-01 | Liver | liver hepatocellular carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TENM4 | SNV | Missense_Mutation | | c.6772N>A | p.Asp2258Asn | p.D2258N | Q6N022 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-FV-A496-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TENM4 | SNV | Missense_Mutation | rs758333727 | c.6739N>T | p.Arg2247Trp | p.R2247W | Q6N022 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-FV-A4ZQ-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TENM4 | SNV | Missense_Mutation | | c.649G>C | p.Asp217His | p.D217H | Q6N022 | protein_coding | tolerated_low_confidence(0.12) | probably_damaging(0.999) | TCGA-UB-A7MB-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Targeted Molecular therapy | sorafenib | PD |
TENM4 | SNV | Missense_Mutation | | c.4217N>A | p.Leu1406Gln | p.L1406Q | Q6N022 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-05-4382-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |